Overview

• Post By : Jatin Mahajan


• Source: J. Mitra & Co. Pvt. Ltd.


• Date: 06 Jun,2025

With a stellar legacy spanning over five decades, 55 patents, and exports to more than 45 countries, J Mitra and Company has become a worldwide pioneer in the in-vitro diagnostics (IVD) sector.

The company has developed a solid reputation for creativity, quality, and affordability in diagnostic solutions. J Mitra focuses on enhancing the speed and precision of their diagnostic kits, and this has helped revolutionize healthcare diagnostics.

Science of Rapid Testing: The Foundation of J Mitra’s Diagnostic Excellence

Science of Rapid Testing

The J Mitra rapid test kits use advanced immunoassay techniques, including fluorescence immunoassays (FIA) and lateral flow immunochromatographic assays, to deliver fast and precise results.

J Mitra tests have been designed to detect specific antigens or antibodies in human fluids, including blood serum and plasma, for early diagnosis, which enables prompt treatment.

 J Mitra’s innovation history includes several critical rapid tests that have proven their effectiveness time and again –

1. The iQuant immunoassay analyzer is India’s first portable diagnostic system based on J Mitra’s partnership with IIT Madras. The cutting-edge iQuant enables qualitative and quantitative testing for 12 parameters through a user-friendly design that delivers fast results and superior sensitivity to standard ELISA methods.
2. The Fourth-generation HIV Ag & Ab Card provides a complete and immediate diagnosis of HIV-1 p24 antigen with IgM, IgG, and IgA antibodies.
3. Rapid test results enable healthcare professionals to initiate timely interventions by reducing the detection period and utilizing both capillary and venous blood samples.
4. The Dengue NS1 Antigen and IgM plus IgG Antibody Detection Rapid self-test kit enables people to conduct the test independently and provides results within 20 minutes of the first appearance of the symptoms. This self-test kit detects all four dengue virus serotypes while maintaining high sensitivity and specificity levels.
5. The rapid antigen test kit for COVID-19 achieved 91.51% sensitivity with 100% specificity. The COVID-19 Microlisa ELISA kit, based on a double-antigen sandwich ELISA, detected IgM, IgG, and IgA antibodies within 90 minutes for qualitative results. The combination of screening and epidemiological research demonstrated a 94.04% sensitivity rate alongside 100% specificity, as validated by ICMR.
6. J Mitra provides different malaria quick test kits that detect Plasmodium falciparum (Pf) and other Plasmodium species (PAN). The sandwich immunoassay-based kits deliver diagnostic results within 20 minutes.
7. The Typhoid and Scrub Typhus Rapid Test Kits use cards to detect diseases and provide 100% sensitivity and specificity and 20-minute result times for the Typhi IgM & IgG Card and Scrub Typhus IgM/IgA Card.

Representative image

J Mitra’s Dedication to Availability, Innovation, and Quality

J Mitra relies heavily on its extensive in-house R&D facility to drive innovation and is strongly supported by research and academic institutions.

As a result, J Mitra has over 65 patents (the highest for any IVD company in India), is a pioneer in IVD test kits in India, and holds a global industry leadership position in its segment. J Mitra’s high-quality kits are not only suited for remote and resource-constrained settings but are also reasonably priced. By focusing on creating point-of-care testing solutions, J Mitra has facilitated ease of use and eliminated the need for specific training and equipment in many cases.

National and Global Influence

J Mitra products have demonstrated accuracy and fast turnaround time for results. This makes them an ideal choice for Governments and global health organizations in their effort to control infectious diseases like HIV, dengue, malaria, typhoid, and COVID-19.

The accuracy and quick turnaround time for the results help decrease the spread of disease and enhance patient outcomes.

For example, the ability of the dengue NS1 Antigen self-test kit to identify infection from the first day of fever onset is vital in averting serious consequences, such as dengue hemorrhagic fever and dengue shock syndrome, which are the leading causes of mortality globally.

Given the global increase in dengue infections, public health depends critically on such advances. Likewise, the company’s COVID-19 and HIV test kits support mass screening and monitoring campaigns. Rapid test kits, combined with sophisticated analyzers such as iQuant, guarantee that both laboratory-based and point-of-care diagnostics are fully covered under their portfolio of offerings.

By combining speed with precision using cutting-edge science and technology, J Mitra and Company has established a leadership position in the in vitro diagnostics (IVD) industry. Supported by decades of research and innovation, their rapid test kits provide dependable, reasonably priced, and easily accessible diagnostic solutions that help address some of the most pressing healthcare challenges worldwide. J Mitra’s test kits enable patients and healthcare professionals to make quick and informed decisions, save lives, and improve global health outcomes.